Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 03 2019Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc....
- Aug 28 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key...
- Aug 12 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today...
- Aug 08 2019- Record quarterly revenue of $6.7 million, up 29% over the prior year
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today...
- Aug 08 2019evo® Cold Chain Management System, Designed for High-Value, Temperature-Sensitive Biologics, Used for Initial Shipments by 50 Cell & Gene Therapy Companies
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that it has executed a...
- Jul 31 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Jul 30 2019Reduced in-transit shipping damage, Extended dynamic thermal performance and Predictive Analytics in Next Generation Dry Vapor Liquid Nitrogen Shippers
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a...
- Jul 23 2019evo® Cold Chain Management System and LifeGuard Same Day Service Reduce Risks for High-Value, Temperature-Sensitive Biologic Drugs
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a...
- Jul 08 2019Acquisition further strengthens portfolio of best in class, proprietary enabling solutions for cell and gene therapy companies
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies,...
- Jun 10 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 30 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 29 2019Cloud-Connected, Smart Shippers and evo.is Real-Time Visibility Platform Improve Quality of Transportation and Delivery of Lifesaving Therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing devices for...
- May 09 2019- Revenue Increased 51% to a Record $5.8 million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices...
- May 02 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Apr 02 2019Gains products that automate the thawing process for high-value biologic therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has closed the previously announced transaction for the acquisition of Astero Bio Corporation ("Astero"), an innovator in...
- Mar 14 2019Revenue Increased 79% for the Year to $19.7 Million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary cell and tissue hypothermic storage and cryopreservation freeze media, today...
- Mar 14 2019Gains products that automate the thawing process for high-value biologic therapies
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife") today announced that it has entered into an agreement to acquire Astero Bio Corporation ("Astero"), a privately-held innovator in the design,...
- Mar 04 2019
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the...
- Feb 19 2019
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that...
- Jan 22 2019FDA Cites Increases in IND Submissions and Anticipated Product Approvals that could benefit BioLife Solutions
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, expects to benefit from new...
- Nov 27 2018Redemption eliminates annual cash dividend payment
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, ("BioLife" or the "Company"),...
- Nov 13 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today announced that...
- Nov 08 2018Revenue increases 79% to a record $5.3 million; achieves net income of $1.2 million
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, today reported...
- Nov 01 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that the...
- Oct 01 2018
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze...
We believe the promise of cell and gene therapies starts with the integrity of a single cell
Advancing the future of cell and gene therapy
The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.
We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.
Streamline workflows and safeguard therapies
GMP-COMPATIBLE
Precision
biopreservation
for
maximum
viability
GMP-COMPATIBLE
Our biopreservation media and storage solutions are engineered to maintain cell integrity and functionality. With GMP-compatible, validated formulations, we help you reduce variability and improve post-thaw recovery, ensuring robust and reproducible outcomes.
CELL VIABILITY
Best
practices
in
cell
processing
CELL VIABILITY
With deep industry experience, regulatory support, and a commitment to innovation, BioLife Solutions is dedicated to supporting bioprocess engineers in overcoming complex manufacturing challenges. Whether optimizing cryopreservation protocols or ensuring the seamless transition from lab to clinic, we are dedicated to your success.
QUALITY & COMPLIANCE
Scalable
manufacturing
and
process
optimization
QUALITY & COMPLIANCE
Enhance efficiency and consistency in your cell processing workflow with our closed-system tools for fluid management and cell processing that are automation ready. Reduce manual handling errors, improve throughput, and achieve higher standards of quality and compliance as you scale towards commercialization.
REGULATORY SUPPORT
Your
partner
in
bioprocess
optimization
REGULATORY SUPPORT
BioLife Solutions delivers specialized tools and expertise to help bioprocess engineers streamline and strengthen biopreservation processes across the cell therapy workflow. From selecting the right biopreservation media to minimizing cell loss during freezing, storage, and transports, our solutions are designed to improve consistency, reduce risk, and support a successful transition from development to clinical application.
Work with experts who understand your biopreservation challenges
Connect with
our
experts
Explore
our
solutions
Collaborative and comprehensive CDMO support
At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.
Regulatory
readiness
Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.
STORE
CellSeal®
CryoCase
Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates
Data-driven
decision making
Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.
